MedTrace Logo

Oral Vancomycin for Preventing Clostridium Difficile Recurrence

NCT03200093 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2021-04-26

No results posted yet for this study

Summary

This study evaluates the role of oral vancomycin in the prevention of recurrent Clostridium difficile for hospitalized patients receiving systemic antibiotic therapy. Half of participants will receive oral vancomycin daily, while the other half will receive a placebo.

Conditions

  • Clostridium Difficile Infection

Interventions

DRUG

Oral Vancomycin

Oral vancomycin solution 125 mg in 2.5 mL combined with 2.5 mL Ora-Sweet. A total of 5 mL combined solution taken by mouth once daily.

DRUG

Placebo

Ora-Sweet 5mL taken by mouth once daily.

Sponsors & Collaborators

  • Rochester General Hospital

    lead OTHER

Principal Investigators

  • Maryrose R Laguio-Vila, MD · Rochester General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-08
Primary Completion
2021-04-22
Completion
2021-04-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03200093 on ClinicalTrials.gov